----

----

| [X]    | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   |
|--------|------------------------------------------------------------------------------------------|
|   | For the quarterly period ended September 30, 2010                                   |
| [ ]    | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |
|   | For the transition period from _____ to _____                                            |

|                    Delaware                       |               26-2443288            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (State or Other Jurisdiction of                                                                                                                                                                                                            | (I.R.S. Employer I.D. No.)                                                                                                                                  |
|   incorporation or organization)                                                                                                                                                                                                 |                                                                                                                                                        |

----

|                                                                                                                                               |   | Page(s) |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------|
|                                                                                                                                               |   |    |
| Consolidated Balance Sheets as of September 30, 2010 (Unaudited) and June 30, 2010                                                                 |   | 2       |
|                                                                                                                                               |   |    |
| Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Three Months Ended September 30, 2010 and 2009 (Unaudited) |   | 3       |
|                                                                                                                                               |   |    |
| Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2010 and 2009 (Unaudited)                                           |   | 4       |
|                                                                                                                                               |   |    |
| Notes to Financial Statements (Unaudited)                                                                                                          |   | 5-7     |

----

| JINZANGHUANG TIBET PHARMACEUTICALS, INC.                                                               |   |
|--------------------------------------------------------------------------------------------------------|--------|
| CONSOLIDATED BALANCE SHEETS                                                                            |   |
|                                                                                                   |   |   |   |   |   |   |
|                                                                                                   |   |   |   |   |   |   |
| ASSETS                                                                                                 |
|                                                                                                   |   | September 30, |   |   | June 30, |   |
|                                                                                                   |   | 2010 |   |   | 2010 |   |
|                                                                                                   |   | (Unaudited) |   |   |   |   |
| CURRENT ASSETS:                                                                                        |   |   |   |   |   |   |
|      Cash                                                                     |   | $ | 30,192 |   |   | $ | 42,184 |   |
|      Accounts receivable                                                      |   |   | 14,371 |   |   |   | - |   |
|      Inventory                                                                |   |   | 285,941 |   |   |   | 305,557 |   |
|      Advance to supplier                                                      |   |   | 250,944 |   |   |   | 239,555 |   |
|      Prepaid expenses and other sundry current assets                         |   |   | 13,453 |   |   |   | 15,351 |   |
|      Deferred tax assets                                                      |   |   | 22,025 |   |   |   | 15,092 |   |
| TOTAL CURRENT ASSETS                                                                                   |   |   | 616,926 |   |   |   | 617,739 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| LONT-TERM ASSETS:                                                                                      |   |   |   |   |   |   |   |   |
|      Property and equipment, net of accumulated depreciation and amortization |   |   | 581,494 |   |   |   | 576,762 |   |
|      Long-term contract                                                       |   |   | 130,988 |   |   |   | 132,570 |   |
| TOTAL LONG-TERM ASSETS                                                                                 |   |   | 712,482 |   |   |   | 709,332 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| TOTAL  ASSETS                                                                                |   | $ | 1,329,408 |   |   | $ | 1,327,071 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES:                                                                                   |   |   |   |   |   |   |   |   |
|      Accrued expenses and other sundry current liabilities                    |   | $ | 86,433 |   |   | $ | 79,451 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| TOTAL CURRENT LIABILITIES AND TOTAL LIABILITIES                                                        |   |   | 86,433 |   |   |   | 79,451 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| STOCKHOLDERS' EQUITY:                                                                                  |   |   |   |   |   |   |   |   |
|    Common stock, $0.001 par value,                                                      |   |   |   |   |   |   |   |   |
|     300,000,000 shares authorized,                                                 |   |   |   |   |   |   |   |   |
|     40,665,063 shares issued and outstanding                                       |   |   | 40,665 |   |   |   | 40,665 |   |
|    Additional paid-in capital                                                           |   |   | 568,077 |   |   |   | 568,077 |   |
|    Accumulated deficit                                                                  |   |   | (151,299 | ) |   |   | (128,285 | ) |
|    Accumulated other comprehensive income                                               |   |   | 7,414 |   |   |   | 3,556 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| TOTAL STOCKHOLDERS' EQUITY OF JINZANGHUANG TIBET PHARMACEUTICALS, INC.                                 |   |   | 464,857 |   |   |   | 484,013 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| NONCONTROLLING INTEREST IN SUBSIDIARY                                                                  |   |   | 778,118 |   |   |   | 763,607 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| TOTAL STOCKHOLDERS' EQUITY                                                                             |   |   | 1,242,975 |   |   |   | 1,247,620 |   |
|                                                                                                   |   |   |   |   |   |   |   |   |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                                             |   | $ | 1,329,408 |   |   | $ | 1,327,071 |   |

----

| JINZANGHUANG TIBET PHARMACEUTICALS, INC.                                  |   |
|---------------------------------------------------------------------------|--------|
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS              |   |
| (Unaudited)                                                               |   |
|                                                                      |   |   |   |   |   |   |
|                                                                      |   |   |   |   |   |   |
|                                                                      |   | THREE MONTHS ENDED September 30, |   |
|                                                                      |   | 2010 |   |   | 2009 |   |
|                                                                      |   |   |   |   |   |   |
| SALES                                                                     |   | $ | 26,673 |   |   | $ | 224,950 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| COSTS of SALES                                                            |   |   | 24,299 |   |   |   | 171,856 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| GROSS PROFIT                                                              |   |   | 2,374 |   |   |   | 53,094 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| COSTS AND EXPENSES                                                        |   |   |   |   |   |   |   |   |
|      General and Administrative Expenses         |   |   | 33,879 |   |   |   | 84,470 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| LOSS BEFORE INCOME TAX                                                    |   |   | (31,505 | ) |   |   | (31,376 | ) |
|                                                                      |   |   |   |   |   |   |   |   |
| INCOME TAX (CREDIT)                                                       |   |   | (6,933 | ) |   |   | 2,236 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| NET LOSS                                                                  |   |   | (24,572 | ) |   |   | (33,612 | ) |
|                                                                      |   |   |   |   |   |   |   |   |
| LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTERESTS          |   |   | (1,558 | ) |   |   | 176 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| NET LOSS ATTRIBUTABLE TO THE COMPANY                                      |   |   | (23,014 | ) |   |   | (33,788 | ) |
|                                                                      |   |   |   |   |   |   |   |   |
| OTHER COMPREHENSIVE INCOME (LOSS)                                         |   |   |   |   |   |   |   |   |
|    Foreign currency translation adjustment                 |   |   | 19,927 |   |   |   | 1,344 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| COMPREHENSIVE LOSS                                                        |   |   | (3,087 | ) |   |   | (32,444 | ) |
|                                                                      |   |   |   |   |   |   |   |   |
| LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS |   |   | 16,069 |   |   |   | 36 |   |
|                                                                      |   |   |   |   |   |   |   |   |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO THE COMPANY                            |   | $ | (19,156 | ) |   | $ | (32,480 | ) |
|                                                                      |   |   |   |   |   |   |   |   |
|                                                                      |   |   |   |   |   |   |   |   |
|                                                                      |   |   |   |   |   |   |   |   |
| Basic and diluted earnings per common share                               |   | $ | (0.00 | ) |   | $ | (0.00 | ) |
|                                                                      |   |   |   |   |   |   |   |   |
| Weighted average number of shares outstanding                             |   |   | 40,665,063 |   |   |   | 40,645,063 |   |

----

| JINZANGHUANG TIBET PHARMACEUTICALS, INC.                                                |   |
|-----------------------------------------------------------------------------------------|--------|
| CONSOLIDATED STATEMENTS OF CASH FLOW                                                    |   |
| (Unaudited)                                                                             |   |
|                                                                                    |   |   |   |   |   |   |
|                                                                                    |   |   |   |   |   |   |
|                                                                                    |   | THREE MONTHS ENDED September 30, |   |
|                                                                                    |   | 2010 |   |   | 2009 |   |
|                                                                                    |   |   |   |   |   |   |
| OPERATING ACTIVITIES:                                                                   |   |   |   |   |   |   |
| Net loss attributable to the Company                                                    |   | $ | (23,014 | ) |   | $ | (33,788 | ) |
| Adjustments to reconcile net loss to net cash used                                      |   |   |   |   |   |   |   |   |
|  in operating activities:                                                          |   |   |   |   |   |   |   |   |
|      Net income(loss) attributable to noncontrolling interests |   |   | (1,558 | ) |   |   | 176 |   |
|      Depreciation and amortization                             |   |   | 4,666 |   |   |   | 7,546 |   |
|      Amortization of long-term contract                        |   |   | 3,743 |   |   |   | - |   |
|      Deferred tax                                              |   |   | (6,933 | ) |   |   | - |   |
| cash used in operating assets and liabilities:                                          |   |   |   |   |   |   |   |   |
|      Accounts receivable                                       |   |   | (14,371 | ) |   |   | (11,206 | ) |
|      Inventory                                                 |   |   | 24,594 |   |   |   | 171,961 |   |
|      Advance to supplier                                       |   |   | (7,485 | ) |   |   | (102,690 | ) |
|      Contract deposit                                          |   |   | - |   |   |   | (146,700 | ) |
|      Prepaid exenses and other sundry current assets           |   |   | 2,144 |   |   |   | (9,273 | ) |
|      Accrued expeses and other sundry current liabilities      |   |   | 6,127 |   |   |   | (574,328 | ) |
| NET CASH USED IN OPERATING ACTIVITIES                                                   |   |   | (12,087 | ) |   |   | (698,302 | ) |
|                                                                                    |   |   |   |   |   |   |   |   |
| FINANCING ACTIVITIES:                                                                   |   |   |   |   |   |   |   |   |
|      Contribution from minority interest                       |   |   | - |   |   |   | 36,675 |   |
|      Repayment to shareholders                                 |   |   | - |   |   |   | (861 | ) |
|      Capital contribution                                      |   |   | - |   |   |   | 738,808 |   |
| NET CASH PROVIDED BY FINANCING ACTIVITIES                                               |   |   | - |   |   |   | 774,622 |   |
|                                                                                    |   |   |   |   |   |   |   |   |
| EFFECT OF EXCHANGE RATE ON CASH                                                         |   |   | 95 |   |   |   | 702 |   |
|                                                                                    |   |   |   |   |   |   |   |   |
| INCREASE (DECREASE) IN CASH                                                             |   |   | (11,992 | ) |   |   | 77,022 |   |
|                                                                                    |   |   |   |   |   |   |   |   |
| CASH - BEGINNING OF PERIOD                                                              |   |   | 42,184 |   |   |   | 25,115 |   |
|                                                                                    |   |   |   |   |   |   |   |   |
| CASH - END OF PERIOD                                                                    |   | $ | 30,192 |   |   | $ | 102,137 |   |
|                                                                                    |   |   |   |   |   |   |   |   |
|                                                                                    |   |   |   |   |   |   |   |   |
| Supplemental disclosures of cash flow information:                                      |   |   |   |   |   |   |   |   |
|    Cash paid for income tax                                              |   | $ | - |   |   | $ | 8,045 |   |

----

----

----

----

|                                        |   | September 30 2010 |   |   | September 30 2009 |    |
|---------------------------------------------|--------|-------------------|--------|--------|-------------------|---------|
|                                        |   |   Rate       |   | Amount |              |    | Rate |   | Amount |   |
| U.S. Statutory rate                         |   | (35               | %)     |   | $                 | (11,026 | ) |   |   | (35 | %) |   |   | (10,972 | ) |
| Tax rate difference between China and U.S.  |   | 9                 | %      |   |              | 2,772   |   |   |   | (3 | %) |   |   | (894 | )  |
| NOL from U.S. with 100% valuation allowance |   | 4                 | %      |   |              | 1,321   |   |   |   | 45 | % |   |   | 14,102 |   |
| Effective tax rate                          |   | (22               | %)     |   |              | (6,933) |   |   |   |     7 | % |   |   | 2,236 |   |

|                                |   | September 30 2010 |   |    | September 30 2009 |   |
|-------------------------------------|--------|-------------------|--------|---------|-------------------|--------|
| Current – foreign             |   | $                 | -      |    |              | $      | 302 |   |
| Deferred – foreign            |   |              | (6,933 | )       |              |   | 1,934 |   |
| Deferred - United States            |   |              | (1,321 | )  |              |   | (14,102 | )  |
| Valuation allowance - United States |   |              | 1,321  |    |              |   | 14,102 |   |
| Total                               |   | $                 | (6,933 | )  |              | $      | 2,236 |   |

----

| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF OPERATIONS |
|---------|--------------------------------------------------------------------------------------------|

----

----

|   | · | Relocate our headquarters from Shangdong to Beijing, where we will have greater access to marketing channels; |
|--------|--------|---------------------------------------------------------------------------------------------------------------|

|   | · | Implement our direct marketing program, including development of an online presence; |
|--------|--------|--------------------------------------------------------------------------------------|

|   | · | Acquire the rights to pharmaceuticals and nutraceuticals that will complement our existing product line; |
|--------|--------|----------------------------------------------------------------------------------------------------------|

|   | · | Carry on clinical trials of pharmaceuticals required to obtain SFDA approval; |
|--------|--------|-------------------------------------------------------------------------------|

|   | · | Establish franchisees throughout China; and |
|--------|--------|---------------------------------------------|

|   | · | Implement an advertising and marketing program adequate to assure us of substantial market presence. |
|--------|--------|------------------------------------------------------------------------------------------------------|

----

| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
|---------|------------------------------------------------------------|

| ITEM 4. | CONTROLS AND PROCEDURES |
|---------|-------------------------|

| 31.1 | Rule 13a-14(a) Certification - CEO |
|------|------------------------------------|
| 31.2 | Rule 13a-14(a) Certification - CFO |
| 32   | Rule 13a-14(b) Certifications      |

----

|                   | JINZANGHUANG TIBET PHARMACEUTICALS, INC.                                                   |
|------------------------|--------------------------------------------------------------------------------------------|
|                   |                                                                                       |
| Date: NOVEMBER 12 2010 | By: /s/ Xue Bangyi                                                                         |
|                   |        Xue Bangyi, Chief Executive Officer              |
|                   |                                                                                       |
| Date: NOVEMBER 12 2010 | By: /s/ Eva Deng                                                                           |
|                   |        Eva Deng, Chief Financial and Accounting Officer |

----